Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study.
Standard
Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. / Eifinger, F; Sreeram, N; Mehler, K; Huenseler, C; Kribs, A; Roth, Bernhard.
In: KLIN PADIATR, Vol. 220, No. 2, 2, 2008, p. 66-69.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study.
AU - Eifinger, F
AU - Sreeram, N
AU - Mehler, K
AU - Huenseler, C
AU - Kribs, A
AU - Roth, Bernhard
PY - 2008
Y1 - 2008
N2 - BACKGROUND: In premature infants with preterm prolonged rupture of membranes, death after birth is often due to persistent pulmonary hyper-tension. PATIENTS: Aerosolized iloprost was used to treat pulmonary hypertension due to prolonged preterm rupture of fetal membranes (7-56 days) in four extremely low-birthweight neonates (23-25 weeks' gestation, weight 448-645 g) under spontaneous breathing supported by nasal continuous positive airway pressure. METHOD: Inhalation dose was 2 microg/kg b.w. and between 44 and 65 inhalations were performed in each patient starting within the first hour of life over a total of several days. Single inhalations lasted 5 min and were not repeated until 60 min had elapsed. RESULTS: After the first inhalation, the PaO2/FiO2 mean ratio increased from 65 (range 35-114) to 194 (148-250) mmHg and oxygenation requirements decreased within the next 7 days. Echocardiography similarly showed reduction in pulmonary resistance. We observed no severe side effects on blood pressure or prolonged bleeding time during inhalation. CONCLUSIONS: Iloprost inhalation might therefore be an additional treatment for improving oxygenation in cases of persistent pulmonary hypertension in extremely low-birthweight infants under spontaneous breathing. Further randomized clinical studies are required to establish the role of iloprost in this setting.
AB - BACKGROUND: In premature infants with preterm prolonged rupture of membranes, death after birth is often due to persistent pulmonary hyper-tension. PATIENTS: Aerosolized iloprost was used to treat pulmonary hypertension due to prolonged preterm rupture of fetal membranes (7-56 days) in four extremely low-birthweight neonates (23-25 weeks' gestation, weight 448-645 g) under spontaneous breathing supported by nasal continuous positive airway pressure. METHOD: Inhalation dose was 2 microg/kg b.w. and between 44 and 65 inhalations were performed in each patient starting within the first hour of life over a total of several days. Single inhalations lasted 5 min and were not repeated until 60 min had elapsed. RESULTS: After the first inhalation, the PaO2/FiO2 mean ratio increased from 65 (range 35-114) to 194 (148-250) mmHg and oxygenation requirements decreased within the next 7 days. Echocardiography similarly showed reduction in pulmonary resistance. We observed no severe side effects on blood pressure or prolonged bleeding time during inhalation. CONCLUSIONS: Iloprost inhalation might therefore be an additional treatment for improving oxygenation in cases of persistent pulmonary hypertension in extremely low-birthweight infants under spontaneous breathing. Further randomized clinical studies are required to establish the role of iloprost in this setting.
M3 - SCORING: Zeitschriftenaufsatz
VL - 220
SP - 66
EP - 69
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 2
M1 - 2
ER -
